Imatinib mesylate (IM), a competitive inhibitor of the BCR-ABL TK activity, is currently used as a first-line therapy for newly diagnosed patients in the chronic phase (CML-CP) (17). The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.